These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31061802)

  • 41. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS; Crawford ED
    Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer.
    McCool R; Fleetwood K; Glanville J; Arber M; Goodall H; Naidoo S
    Value Health; 2018 Oct; 21(10):1259-1268. PubMed ID: 30314628
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Modern treatment of metastatic hormone-sensitive prostate cancer].
    Küronya Z; Bíró K; Géczi L; Maráz A
    Orv Hetil; 2018 Oct; 159(41):1664-1671. PubMed ID: 30295043
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy.
    Shiota M; Yokomizo A; Eto M
    Front Oncol; 2015; 5():304. PubMed ID: 26793621
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contemporary agents in the management of metastatic castration-resistant prostate cancer.
    Kapoor A; Wu C; Shayegan B; Rybak AP
    Can Urol Assoc J; 2016; 10(11-12):E414-E423. PubMed ID: 28096932
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel.
    Li JR; Chiu KY; Wang SS; Yang CK; Chen CS; Ho HC; Hung CF; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Chang CH; Hsu CY; Ou YC
    Front Pharmacol; 2017; 8():836. PubMed ID: 29213237
    [No Abstract]   [Full Text] [Related]  

  • 47. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
    Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
    Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard.
    Mottet N; De Santis M; Briers E; Bourke L; Gillessen S; Grummet JP; Lam TB; van der Poel HG; Rouvière O; van den Bergh RCN; Cornford P
    Eur Urol; 2018 Mar; 73(3):316-321. PubMed ID: 29103760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations.
    Castellan P; Marchioni M; Castellucci R; De Francesco P; Iantorno R; Schips L; Cindolo L
    Ther Clin Risk Manag; 2018; 14():2341-2347. PubMed ID: 30584309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Medical management of metastatic prostate cancer.
    Body A; Pranavan G; Tan TH; Slobodian P
    Aust Prescr; 2018 Oct; 41(5):154-159. PubMed ID: 30410212
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From "All-Comers" to "Personalized" Approach.
    Harada K; Shiota M; Minato A; Matsumoto M; Tomisaki I; Fujisawa M; Fujimoto N
    Onco Targets Ther; 2021; 14():2967-2974. PubMed ID: 33981146
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus.
    Desai C; Vaid AK; Biswas G; Batra S; Dattatreya PS; Mohapatra PN; Dabkara D; Gore A; Bhagat SB; Patil S; Barkate H
    Oncol Ther; 2022 Jun; 10(1):143-165. PubMed ID: 35025089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proper Sequencing of Treatment for Castrate Resistant Prostate Cancer.
    Shore ND; Cookson MS
    Urol Pract; 2014 May; 1(1):2-6. PubMed ID: 37533220
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223.
    Mukherji D; El Dika I; Temraz S; Haidar M; Shamseddine A
    Ther Clin Risk Manag; 2014; 10():373-80. PubMed ID: 24920911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide.
    Gul A; Garcia JA; Barata PC
    Cancer Manag Res; 2019; 11():7253-7262. PubMed ID: 31534371
    [TBL] [Abstract][Full Text] [Related]  

  • 58. WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?
    Gamulin M; Bebek M; Gnjidic M
    Acta Clin Croat; 2019 Nov; 58(Suppl 2):73-75. PubMed ID: 34975202
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces.
    Woon DTS; Chandrasekar T; Aaron L; Basappa NS; Chi KN; Conter HJ; Gotto G; Hotte SJ; Malone S; Saad F; Shayegan B; Park-Wyllie L; Hamilton RJ
    Can Urol Assoc J; 2018 Oct; 12(10):328-336. PubMed ID: 29688882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE.
    Puente J; Anido U; Climent MÁ; Gonzalez-Billalabeitia E; Lainez N; Lambea J; Maroto JP; Mendez-Vidal MJ; Montesa Á; Rodriguez A; Zambrana C; González-Del-Alba A
    Ther Adv Med Oncol; 2020; 12():1758835920920067. PubMed ID: 33014145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.